Trials that involve IMPs approved in Switzerland, if: a) Administration deviates from SPC specifications and one or more of the criteria listed above are not fulfilled.
Trials that involve
IMPs not yet approved in Switzerland.
OECD
Category A: Clinical trials on authorized medicinal products (according to national or regional regulations) tested in accordance with their marketing authorization.
Category B: concerns clinical trials on authorized medicinal products tested according to treatment regimens outside their marketing authorization (in terms of population, condition, administration, or dosage):
1. supported by published evidence or guidance or established medical practice; 2. not supported by published evidence or guidance or established medical practice 
EU -Regulation
'Low-intervention clinical trial' means a clinical trial which fulfils all of the following conditions: (a) the investigational medicinal products, excluding placebos, are authorized; (b) according to the protocol of the clinical trial, (i)the investigational medicinal products are used in accordance with the terms of the marketing authorization; or (ii) the use of the investigational medicinal products is evidence-based and supported by published scientific evidence on the safety and efficacy of those investigational medicinal products in any of the Member States concerned; and (c) the additional diagnostic or monitoring procedures do not pose more than minimal additional risk or burden to the safety of the subjects compared to normal clinical practice in any Member State concerned.
Clinical trials that are not low-intervention clinical trials: (Clinical trials with non-authorized investigational medicinal products or placebos)
product, that can be applied in legislation or regulation in a common manner across countries, with (B) a trial-specific approach that considers a large number of other issues such as additional diagnostic procedures, specific populations concerned, or informed consent."; 3 Principles for risk assessment include: the risk to participant safety in relation to the investigational medicinal product, all other risks related to the design and methods of the trial (including risks to participants safety and rights, as well as reliability of results).  Lies within the therapeutic range as specified in the SPC CATEGORY A  Is lower than specified in the SPC CATEGORY A  Is higher than specified in the SPC CATEGORY B Dosage of IMP by NOT self-limiting disease or condition 7. In case the disease or condition is NOT self-limiting, please indicate if the IMP dosage:
Web appendix 1b. Risk categories for clinical trials with medical devices and other interventions according to draft Clinical Trials Ordinance

Medical device
 Lies within the therapeutic range as specified in the SPC CATEGORY A  Is lower than specified in the SPC CATEGORY B  Is higher than specified in the SPC CATEGORY B report SAEs to ethics committee; report fatal SUSARS to ethics committee; annual safety report to ethics committee 
Resulting risk category:
 CATEGORY A  CATEGORY B  No  CATEGORY B
